Palomar Holdings reports strong earnings growth, premium valuations, and strategic expansion in crop and Surety insurance, highlighting its robust position in specialty insurance markets.

Exact Sciences gains Buy ratings as Cologuard Plus expands in-network Medicare Advantage coverage, boosting reimbursement and revenue potential in cancer screening diagnostics.

Kansas City Life Insurance experiences significant decline in short interest and reports recent financial results with modest stock trading performance and dividend payout. Analysts maintain a Hold rating amid cautious market sentiment.

Truist lowers Centene price target to $35 from $42 following Q2 results, citing ongoing cost trend challenges but strong Prescription Drug Plan and Medicare Advantage performance. Buy rating maintained.

Explore why Lincoln National, Lemonade, and AXIS Capital stocks require caution in portfolios amid market gains and risk exposures in the insurance sector.

Barclays cuts price target on F&G Annuities & Life following mixed quarterly earnings. Explore insights on stock performance, insider trades, and institutional ownership in the insurance sector.

UnitedHealth Group's stock has dropped over 50% in 2024 amid operational disruptions and DOJ probes, despite strong ROCE. Insights on regulatory risks, Medicare cost pressures, and valuation outlook for investors.

FG CEO Christopher O Blunt makes significant stock purchase amid Q1 loss; firm focuses on strategic capital allocation and managing margin compression while maintaining asset growth.

TD Cowen lowers UnitedHealth stock rating and price target due to increased risk and regulatory issues in Medicare Advantage and Medicaid sectors, amid ongoing criminal investigation. Brokerages maintain an outperform stance with long-term valuation upside noted.

UnitedHealth Group stock falls sharply as CEO changes and 2025 guidance withdrawal increase uncertainty. Analysis of implications for the health insurance market.